News & Information | START In The News

October 17th, 2013
By: News Release

START Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting

(SAN ANTONIO, TX) October 17, 2013 -- South Texas Accelerated Research Therapeutics (START), a Phase I medical oncology program with clinic sites in San Antonio, Texas, Madrid, Spain and Shanghai, China, announced today that it will be presenting 7 posters and 1 abstract at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 19-23 in Boston, MA. 

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organization for Research and Treatment of Cancer, the 2013 Molecular Targets and Cancer Therapeutics conference will bring together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

With its global network of sites, START conducts the world's largest -- and the only 24-hour -- Phase I medical oncology program.

Presentation Details

Presentation

Presenter 

Session

Sun, Oct 20, 12:30 - 3:00 PM
A111 - Effects of unconjugated antibody pretreatment to reduce ADC-related toxicity: Preclinical effects of trastuzumab on T-DM1 activity in low passage breast PDX models

Roger Chavez1, Michael J. Wick1, Teresa L. Vaught1, Anthony W. Tolcher1, Meredith P. Tolcher1, Armando Diaz1, Drew Rasco1, Amita Patnaik1, Gladys Rodriguez2, Lon Smith2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session A
PO.35. EGFR / Her2 1
Sun, Oct 20, 12:30 - 3:00 PM

Tue, Oct 22, 12:30 - 3:00 PM
C104 - Preclinical sensitivity of low and high-HER2 expressing START-PDX breast models to T-DM1 and effects of HER3 expression on drug anti-tumor activity

Michael J. Wick1, Jennifer Brown1, Teresa L. Vaught1, Justin Meade1, Anthony W. Tolcher1, Drew Rasco1, Amita Patnaik1, Amy Lang2, Murali Beeram2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session C
PO.34. Drug Screening 2
Tue, Oct 22, 12:30 - 3:00 PM

Tue, Oct 22, 12:30 - 3:00 PM
C10 - Establishment and characterization of melanoma patient-derived xenograft (PDX) model sets: correlation with clinical response and progression using serial biopsy sampling

Michael J. Wick1, Justin Meade1, Jennifer Brown1, Teresa L. Vaught1, Anthony W. Tolcher1, Lizette Gamez1, Drew Rasco1, Amita Patnaik1, Ronald Drengler2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session C
PO.06. Animal Models 3
Tue, Oct 22, 12:30 - 3:00 PM

Sun, Oct 20, 12:30 - 3:00 PM
A105 - Establishment, characterization and clinical correlation of a panel of gynecologic patient-derived xenograft (PDX) models

Michael J. Wick1, Abbey Felder1, Alyssa Moriarty1, Teresa L. Vaught1, Anthony W. Tolcher1, Drew` Rasco1, Amita Patnaik1, Allen J. White2, James Mark2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session A
PO.33. Drug Screening 1
Sun, Oct 20, 12:30 - 3:00 PM

Sun, Oct 20, 12:30 - 3:00 PM
A13 - Establishment and characterization of a panel of melanoma patient-derived xenograft (PDX) models

Lizette Gamez1, Michael J. Wick1, Teresa L. Vaught1, Monica Farley1, Anthony W. Tolcher1, Drew Rasco1, Amita Patnaik1, Alex Miller2, Ron Drengler2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session A
PO.04. Animal Models 1
Sun, Oct 20, 12:30 - 3:00 PM

Sun, Oct 20, 12:30 - 3:00 PM
A107 - In vivo screen of regorafenib in a panel of low passage START-PDX colorectal models: Working to identify a sensitive patient subpopulation

Michael J. Wick1, Lizette Gamez1, Armando Diaz1, Teresa L. Vaught1, Anthony W. Tolcher1, Drew Rasco1, Amita Patnaik1, Lon Smith2, Ron Drengler2, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX

Poster Session A
PO.33. Drug Screening 1
Sun, Oct 20, 12:30 - 3:00 PM

Sun, Oct 20, 12:30 - 3:00 PM
A106 - Utilization of low passage adenoid cystic carcinoma (ACC) models to identify novel therapies

Justin Meade1, Michael J. Wick1, Teresa L. Vaught1, Jennifer Carlile1, Anthony W. Tolcher1, Drew Rasco1, Amita Patnaik1, Jeffrey Kaufman2, Chris Moskaluk3, Kyriakos P. Papadopoulos1. 1South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 2Adenoid Cystic Carcinoma Research Foundation, Needham, MA; 3University of Virginia, Charlottesville, VA

Poster Session A
PO.33. Drug Screening 1
Sun, Oct 20, 12:30 - 3:00 PM

Sun, Oct 20, 12:30 - 3:00 PM
A84 - Nanoparticles-TRAIL demonstrated superior anti-tumor activity in champions and START tumor graft models

Jay A. Friedman1, Michael Wick2, Lizette Gamez2, Rodger Chaves2, Elizabeth Bruckheimer1, Shifra Kleinman3, Benny Perlstein3. 1Champions Oncology, Inc., Baltimore, MD; 2South Texas Accelerated Research Therapeutics (START), San Antonio, TX; 3Nanothera Ltd., Nes-Ziona, Israel

Poster Session A
PO.27. Drug Delivery
Sun, Oct 20, 12:30 - 3:00 P

Sun, Oct 20, 12:30 - 3:00 PM
A73 - A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870)

Valentina Boni1, Olivier Rixe2, Drew Rasco3, Carlos Gomez-Roca4, Emiliano Calvo1, John C. Morris2, Anthony W. Tolcher3, Sylvie Assadourian5, Helene Guillemin5, Jean-Pierre Delord4. 1START Madrid, Madrid, Spain; 2University of Cincinnati Cancer Institute, Cincinnati, OH; 3START San Antonio, San Antonio, TX; 4Institut Claudius Regaud, Toulouse, France; 5Sanofi Oncology, Vitry sur Seine, France

 

 "This is an outstanding accomplishment for any institution involved in clinical cancer research in the world and reflects the hard work of START researchers throughout the world," said  START's director of clinical research, Anthony W. Tolcher, MD. 

The mission of START is to accelerate the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START operates under the clinical leadership of Dr. Anthony W. Tolcher, Dr. Amita Patnaik, Dr. Kyriakos P. Papadopoulos and Dr. Drew Rasco, and consists of a team of highly trained staff with extensive experience in Phase I clinical trials research.


ABOUT START

START is a global, 24-hour Phase I research organization focused on accelerating the development of new anticancer drugs with the purpose of improving quality of life and survival for patients with cancer. START operates under the leadership of Dr. Anthony W. Tolcher, Dr. Amita Patnaik, Dr. Kyriakos P. Papadopoulos and Dr. Drew Rasco and consists of a team of highly trained staff with extensive experience in Phase I clinical trials research. For more information please visit www.startthecure.com. For information on START Shanghai, visit www.startshanghai.cn and for information on START Madrid visit www.startmadrid.com.